Home › Funds › ProShares › ProShares Ultra Nasdaq Biotechnology
Fund family: ProShares · Filed by PROSHARES TRUST (CIK 1174610) · SEC series S000018718
Ticker: BIB (C000051848)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,857 with, 9 against, 0 abstentions (not counted as with management); 4 items carried no recommendation. Shareholder proposals: 2 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as ProShares’s manager page (303,945 ballot items across 135 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | ProShares | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 76.7% | 1,762 | 91.4% | 279,029 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 10.6% | 4,043 |
Each ballot item this fund voted is set against the votes of the other ProShares funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most ProShares funds on all 1,363 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 82.5% of this fund’s 1,866 such votes could be given a sector; the other 327 (17.5%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 1,487 | 9 | 0.6% |
| Industrials | 42 | 0 | 0.0% |
| Technology | 10 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 1,051 | 3 |
| Audit-related | 267 | 0 |
| Say-on-Pay | 231 | 0 |
| Compensation | 150 | 0 |
| Corporate Governance | 99 | 4 |
| Capital Structure | 81 | 0 |
| Extraordinary Transactions | 17 | 0 |
| Shareholder Rights and Defenses | 3 | 0 |
| Other Social Issues | 2 | 1 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Gilead Sciences, Inc. | April 30, 2026 | $7M | 15 | 3 |
| Amgen Inc. | May 19, 2026 | $6M | 15 | 1 |
| Vertex Pharmaceuticals Incorporated | May 13, 2026 | $6M | 14 | 1 |
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $4M | 7 | 0 |
| Moderna, Inc. | May 6, 2026 | $4M | 5 | 0 |
| Moderna, Inc. | November 12, 2025 | $3M | 2 | 0 |
| Biogen Inc. | June 9, 2026 | $2M | 12 | 0 |
| Illumina, Inc. | May 21, 2026 | $1M | 11 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 15, 2026 | Medpace Holdings, Inc. | Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposal | For | Against |
| June 9, 2026 | Pacira Biosciences, Inc. | Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Oliver Benton Curtis III Shareholder proposal | Withhold | For |
| June 9, 2026 | Pacira Biosciences, Inc. | Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Eric de Armas Shareholder proposal | Withhold | For |
Meetings with a proxy contest or competing nominees (2 in 2025-2026), and how the fund voted the items on its ballot.
1,902 ballot items at 267 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, ProShares Ultra Nasdaq Biotechnology (BIB) voted at 267 shareholder meetings of 255 companies, on 1,902 ballot items in all. Where management made a recommendation, the fund followed it on 99.5% of the items and voted against it 9 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 9 shareholder proposals. It voted FOR the board's own proposals less often than ProShares's funds as a whole (76.7% against 91.4%). It voted the same way as most ProShares funds on every item where a comparison was possible. 2 of its meetings were contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of ProShares’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.